Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET ENCORE-UC: Phase 3 study of JNJ-78934804 in moderately to severely active ulcerative colitis
CTR20262546Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab + golimumab, guselkumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
guselkumab + golimumabguselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20262546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262546.